Fuelling the growth of early stage data-driven startups
OUR THESIS
Adrenaline VC is an early and growth stage investor in leading UK based data driven health and engineering businesses. We invest in the most ambitious entrepreneurs and breakthrough technologies.
We have a unique approach to investing, working closely with our companies to provide hands on support and a collaborative ecosystem.
OUR TEAM
David Peerless
David has spent the last 15 years working in investment banking and fund management and, as an equity analyst, was involved in IPOs of healthcare companies in London, Hong Kong and New York. Previously, he managed the world’s largest brand protection program on behalf of Procter & Gamble, in China. He is a guest lecturer at Manchester Business School, where he has lectured on global healthcare systems, and is Director of Boustead Capital Markets LLP. David has a MBA from Manchester Business School and MA (Hons) in Chinese from The University of Edinburgh.
Steve Everhard
Steve has over 40 years’ experience working with technology firms as an engineer and advisor. His early career was as EMEA lead of Media Marketing at Apple. He has worked for MasterCard as Senior Vice President in senior technology and related roles. For the last ten years, Steve has been working closely with early stage technology businesses as a Fellow of The Royal College of the Arts and Director of Dreamstake. He mentors start-ups on a regular basis and helps with investment readiness.
Paul Dowling
Paul has over 30 years experience of working in technology and management consulting firms. He has also spent the last 10 years working with start-up founders and investors in the European technology start-up eco-system. He is a regular speaker at international start-up events and mentors several leading accelerators. Paul is passionate about the potential for large and medium sized organisations to innovate through artificial intelligence and insights gained through data science.
Bradley Hardiman
A biochemist by training, Bradley started his career working for the world’s largest pharmaceutical companies. He spent the last 17 years commercialising research from the university sector. This included 7 ½ years within the seed funds team at Cambridge Enterprise, the commercialisation arm of the University of Cambridge. There, he invested in life science and healthcare companies founded on university technology. Most recently, he was Managing Partner of the Innovation Fund at Future Care Capital, a healthcare advocacy and policy charity.
ADVISORS
Sarah Haywood
Sarah Haywood is Managing Director for Advanced Oxford, a group of senior leaders from the area’s major knowledge-intensive businesses and, since 2014, has been an Executive Director with MedCity, the life sciences cluster organisation for London and the greater south east of England. She is also a member of the Management Board for DigitalHealth.London. Sarah started her career in the NHS and undertook the NHS General Management Training Scheme in NHS Wales. She worked in a number of NHS Trusts, including Great Ormond Street NHS Trust, prior to moving into the pharmaceuticals industry, where she had the role of Operations Head for a drug discovery unit within Novartis Pharmaceuticals. Sarah then moved into government, working as a senior civil servant in a number of policy teams.
Sarah studied Biology at the Oxford University and also has a Post-graduate Diploma in Management (Health) and an MA in Human Resources Management and Strategy. She is a Chartered Fellow of the Chartered Management Institute, and was named on the Progress 1000 for 2019, The Evening Standard’s list of the most influential people, for her work with MedCity.
Theodorus Kasimatis
Theodoros Kasimatis is a Locum Consultant Nephrologist at Guy’s Hospital. He has deep clinical and translational knowledge of Nephrology, Dialysis and Transplantation. His clinical experience at consultant level spans several years. He has a comprehensive translational background in Nephrology and Transplantation/Immunology at the preclinical and clinical drug development stages through his postgraduate studies and the Research Fellowship at the MRC Centre for Transplantation at King’s College London. Theo has intimate knowledge of scientific, regulatory and operational aspects of conducting multicentre Phase 2, 3 and 4 clinical trials.
Theo has an MPhil in Pharmacology and a PhD in the molecular signalling of renal fibrosis from Patras Medical School, Greece, and has an extensive track record of publications in peer reviewed journals and Medical Textbooks. He has a continuous commitment to learning and to leading teams to excellence in patient care.
Stuart Niman
Stuart Niman is a Bond market professional . Well known for superior risk-adjusted returns and Capital preservation around risk-off events . Passionate about clients and mutuality. Stuart previously worked for Blackrock for 12 years and had 8 years prior to Blackrock in the Building Society sector.
Stuart has been an avid Technology investor for many years. He has been a long time supporter of the technologies emanating from Cambridge and has a wide ranging portfolio. He has enjoyed 6 successful exits in the the last 5 years. He is an impact investor.
Stuart was educated at Manchester Grammar School and received a First studying Maths at Trinity College , Cambridge. He likes Chess , Golf , playing Guitar , Problem solving and travelling.
Caroline Quest
Caroline Quest specialises in knowledge exchange, entrepreneurship, research management and IP commercialisation. Caroline’s career includes, Director of Knowledge Transfer, King’s College London; Managing Director of Queen Mary Innovation Ltd and Director of Research and Enterprise, University of Leicester. She has founded numerous successful ventures and enterprises including the incubator Queen Mary Biosciences. Caroline has also been a non-executive director of over 25 companies and has mentored many more. She is currently Director of Research and Enterprise Services at the University of Bath.
CONNECT WITH US
If you're an early stage data driven health or engineering start up, we want to hear from you.
We invest in purpose-led founders obsessed with solving hard problems at scale by creating products and companies that address societal challenges. We're passionate about the power of harnessing data to transform the way people live and work, on a massive scale.
We look for founders with an elusive combination of qualities that will enable them to beat the odds to build large, high impact companies.
